Generex Biotechnology Corporation has announced publication of a follow-up study from a Phase I clinical trial of the immunotherapeutic agent AE37 in patients with prostate cancer. The study demonstrates an association between a specific immune response generated by AE37 and improved overall survival.
A prior study showed that AE37-immunized patients had better overall and disease-free survival as a group than would be expected from their disease status and the current study shows that patients with the strongest immunological response did the best. In particular, both the presence of AE37-induced T cells in peripheral blood as well as a robust delayed type hypersensitivity (DTH) response elicited by AE37 correlated significantly with overall survival.
The authors point out the importance of CD4+ T cells in developing a good DTH response. AE37 was developed using the Antigen Express Ii-Key technology platform that ensures robust, specific CD4+ T cell activation.
The current report expands upon prior studies on the results of a Phase I trial of AE37 in patients with prostate cancer.
AE37 is also the subject of a controlled, randomized Phase II trial to prevent recurrence in patients who have had breast cancer. That study has shown an encouraging trend toward preventing relapse, particularly in patients with low levels of HER2 expression and in triple negative patients. The search for reliable biomarkers is a key priority in the emerging field of cancer immunotherapy.
Article: "AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction," Cancer Immunology, Immunotherapy July 23, 2014.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Dopamine Receptor Agonist Drugs Linked To Gambling And Hypersexuality
- What's Hiding Under The Clouds Of Venus - Heavy Metal Frost?
- Ashes And Vegetables: The Diet Of Roman Gladiators Was Rather Poor
- New Pill-only Regimens Cure Patients With Hardest-to-treat Hepatitis C Infection
- Flow Machine: Hacking The Human Brain For Healing And Wellbeing
- Moderate Pot Use By Adolescents Doesn't Hurt IQ
- Government Math: More Will Lose Health Insurance Than Gained It If ACA Subsidies Are Eliminated
- "Since there's no actual link between vaccines and autism, I think the phrase Vaccines have been..."
- "I'll not argue that humanity made God in their image, because we sought to explain something we..."
- "I think we all are atheist, agnostics, and believers throughout our life time. I also, think some..."
- "The scenario mentioned above (Poor person shows up at emergency room with a fever... No health..."
- "Actually, I used to believe. It was what I was taught as a child and I was raised a Christian...."
- Mutagenesis: One way Europeans wish it was 1936 again
- Closer examination of risk factors for Latinos underscores cultural diversity
- Saving bees requires less pesticides, changing farming
- Could GM plants replace airport security scanners?
- In a battle of brains, chimpanzees match human toddlers
- ‘Urban farmers’ behind GMO labeling initiatives
- Alternate approach to traditional CPR saves lives
- Once CD8 T cells take on one virus, they'll fight others too
- 11 million will lose health insurance if ACA subsidies are eliminated, study finds
- Two Michigan high school students develop screening tools to detect lung and heart disease
- Even depressed people believe that life gets better